156 related articles for article (PubMed ID: 37887342)
1. Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma.
Dumitru CA; Schröder H; Schäfer FTA; Aust JF; Kreße N; Siebert CLR; Stein KP; Haghikia A; Wilkens L; Mawrin C; Sandalcioglu IE
Cells; 2023 Oct; 12(20):. PubMed ID: 37887342
[TBL] [Abstract][Full Text] [Related]
2. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells.
You JH; Lee J; Roh JL
J Exp Clin Cancer Res; 2021 Nov; 40(1):350. PubMed ID: 34749765
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.
Tsai HW; Ho CL; Cheng SW; Lin YJ; Chen CC; Cheng PN; Yen CJ; Chang TT; Chiang PM; Chan SH; Ho CH; Chen SH; Wang YW; Chow NH; Lin JC
World J Gastroenterol; 2018 Mar; 24(10):1152-1166. PubMed ID: 29563759
[TBL] [Abstract][Full Text] [Related]
4. PLOD2 Is a Prognostic Marker in Glioblastoma That Modulates the Immune Microenvironment and Tumor Progression.
Kreße N; Schröder H; Stein KP; Wilkens L; Mawrin C; Sandalcioglu IE; Dumitru CA
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682709
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors.
Friel AM; Zhang L; Pru CA; Clark NC; McCallum ML; Blok LJ; Shioda T; Peluso JJ; Rueda BR; Pru JK
Cancer Lett; 2015 Jan; 356(2 Pt B):434-42. PubMed ID: 25304370
[TBL] [Abstract][Full Text] [Related]
6. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Neubauer H; Adam G; Seeger H; Mueck AO; Solomayer E; Wallwiener D; Cahill MA; Fehm T
Climacteric; 2009 Jun; 12(3):230-9. PubMed ID: 19340614
[TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.
Asperger H; Stamm N; Gierke B; Pawlak M; Hofmann U; Zanger UM; Marton A; Katona RL; Buhala A; Vizler C; Cieslik JP; Ruckhäberle E; Niederacher D; Fehm T; Neubauer H; Ludescher M
Breast Cancer Res; 2020 Jul; 22(1):75. PubMed ID: 32660617
[TBL] [Abstract][Full Text] [Related]
8. Ultrasound-triggered microbubble destruction enhances the radiosensitivity of glioblastoma by inhibiting PGRMC1-mediated autophagy in vitro and in vivo.
He Y; Dong XH; Zhu Q; Xu YL; Chen ML; Liu Z
Mil Med Res; 2022 Feb; 9(1):9. PubMed ID: 35152910
[TBL] [Abstract][Full Text] [Related]
9. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.
Zhao Y; Ruan X; Cheng J; Xu X; Gu M; Mueck AO
Climacteric; 2023 Apr; 26(2):135-142. PubMed ID: 36724820
[TBL] [Abstract][Full Text] [Related]
10. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients.
Mir SU; Ahmed IS; Arnold S; Craven RJ
Int J Cancer; 2012 Jul; 131(2):E1-9. PubMed ID: 21918976
[TBL] [Abstract][Full Text] [Related]
11. Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics.
Cai G; Yang X; Ruan X; Wang J; Fang Y; Wei Y; Zhang Y; Gu M; Mueck AO
Maturitas; 2020 Oct; 140():64-71. PubMed ID: 32972637
[TBL] [Abstract][Full Text] [Related]
12. Progesterone induced Warburg effect in HEK293 cells is associated with post-translational modifications and proteasomal degradation of progesterone receptor membrane component 1.
Sabbir MG
J Steroid Biochem Mol Biol; 2019 Jul; 191():105376. PubMed ID: 31067491
[TBL] [Abstract][Full Text] [Related]
13. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule.
Ahmed IS; Rohe HJ; Twist KE; Mattingly MN; Craven RJ
J Pharmacol Exp Ther; 2010 May; 333(2):564-73. PubMed ID: 20164297
[TBL] [Abstract][Full Text] [Related]
15. Progesterone regulation of progesterone receptor membrane component 1 (PGRMC1) sumoylation and transcriptional activity in spontaneously immortalized granulosa cells.
Peluso JJ; Lodde V; Liu X
Endocrinology; 2012 Aug; 153(8):3929-39. PubMed ID: 22719051
[TBL] [Abstract][Full Text] [Related]
16. Flotillin-1 is a prognostic biomarker for glioblastoma and promotes cancer development through enhancing invasion and altering tumour microenvironment.
Wang R; Chen Z; Zhang Y; Xiao S; Zhang W; Hu X; Xiao Q; Liu Q; Wang X
J Cell Mol Med; 2023 Feb; 27(3):392-402. PubMed ID: 36647700
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer.
Ruan X; Zhang Y; Mueck AO; Willibald M; Seeger H; Fehm T; Brucker S; Neubauer H
Menopause; 2017 Feb; 24(2):203-209. PubMed ID: 27749742
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
19. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
20. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
